Participants must be males or non-pregnant females at least 18 years of age.
Diagnosis of non-inflammatory breast adenocarcinoma or in situ breast cancer which will be treated by radiotherapy after operation.
Patient had unilateral breast conservation surgery with or without adjuvant or neoadjuvant chemotherapy or hormonal treatment.
Patients were scheduled to receive at least five sessions of radiotherapy per week (1 session per day) for at least four weeks using standard irradiation fraction (with at least 1.8 Gy per session) for total dose of at least 45 Gy.
Participant must give informed consent.
You may not be if
Bilateral breast cancer
Previous radiotherapy to the chest
Prior breast reconstructions, implants, and/or expanders
Known radiosensitivity syndromes (e.g. Ataxia-telangiectasia)
Collagen vascular disease, vasculitis, unhealed surgical sites, breast infections or systemic lupus erythematosus (SLE)
Participation in any clinical trial in the prior 30 days from baseline.
Any condition that, in the judgement of the investigator could impose hazards to the patient if study therapy is initiated or affect the participation of the patient in the study.
Clareo Health | Quantifying Radiation-Induced Skin Reactions: Establishing the Foundation for Future Prediction Models
